LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. — Investor Relations & Filings
About LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD.
Liaoning Chengda Biotechnology Co., Ltd. specializes in the research, development, manufacturing, and commercialization of human vaccines. The company is a global leader in the production of purified human rabies vaccines using large-scale Vero cell bioreactor technology. Its product portfolio includes inactivated Japanese encephalitis vaccines and various pipeline candidates targeting infectious diseases. Utilizing advanced cell culture platforms, the company maintains high-volume production capabilities while adhering to international quality standards. Its products are distributed extensively across domestic markets and exported to numerous countries worldwide. The organization focuses on technological innovation in biopharmaceuticals to address public health needs through the provision of safe and effective immunization solutions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 辽宁成大生物股份有限公司关于购买董事、高级管理人员责任保险的公告 | 2026-04-20 | Chinese | |
| 辽宁成大生物股份有限公司2025年度董事会审计委员会履职报告 | 2026-04-20 | Chinese | |
| 辽宁成大生物股份有限公司2025年年度报告摘要 | 2026-04-20 | Chinese | |
| 辽宁成大生物股份有限公司2025年度募集资金存放与实际使用情况的专项报告 | 2026-04-20 | Chinese | |
| 致同会计师事务所（特殊普通合伙）关于辽宁成大生物股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告 | 2026-04-20 | Chinese | |
| 辽宁成大生物股份有限公司章程 | 2026-04-20 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39731132 | 辽宁成大生物股份有限公司关于购买董事、高级管理人员责任保险的公告 | 2026-04-20 | Chinese | ||
| 39731131 | 辽宁成大生物股份有限公司2025年度董事会审计委员会履职报告 | 2026-04-20 | Chinese | ||
| 39731118 | 辽宁成大生物股份有限公司2025年年度报告摘要 | 2026-04-20 | Chinese | ||
| 39731115 | 辽宁成大生物股份有限公司2025年度募集资金存放与实际使用情况的专项报告 | 2026-04-20 | Chinese | ||
| 39731105 | 致同会计师事务所（特殊普通合伙）关于辽宁成大生物股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告 | 2026-04-20 | Chinese | ||
| 39731094 | 辽宁成大生物股份有限公司章程 | 2026-04-20 | Chinese | ||
| 39731082 | 辽宁成大生物股份有限公司2025年度独立董事述职报告(陈克兢） | 2026-04-20 | Chinese | ||
| 39731075 | 致同会计师事务所（特殊普通合伙）关于辽宁成大生物股份有限公司2025年度审计报告 | 2026-04-20 | Chinese | ||
| 39730768 | 辽宁成大生物股份有限公司关于召开2025年年度股东会的通知 | 2026-04-20 | Chinese | ||
| 39730766 | 致同会计师事务所（特殊普通合伙）关于辽宁成大生物股份有限公司2025年度内部控制审计报告 | 2026-04-20 | Chinese | ||
| 39730712 | 辽宁成大生物股份有限公司关于修订《公司章程》及部分治理制度的公告 | 2026-04-20 | Chinese | ||
| 39730710 | 辽宁成大生物股份有限公司2025年度独立董事述职报告(刘晓辉) | 2026-04-20 | Chinese | ||
| 39730692 | 辽宁成大生物股份有限公司2025年度社会责任报告 | 2026-04-20 | Chinese | ||
| 39729701 | 辽宁成大生物股份有限公司关于2025年度会计师事务所履职情况评估报告 | 2026-04-20 | Chinese | ||
| 39729699 | 辽宁成大生物股份有限公司关于向广发证券股份有限公司购买理财产品暨关联交易的公告 | 2026-04-20 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58620/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58620 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58620 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58620 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58620}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. (id: 58620)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.